| Age | Gender | Classification | Cytogenetics | Bm blast% | Plt/mcL | Hgb g/dL | Time to progression | Treatment | Outcome | Reference |
| 74 | M | RCMD | 44, XY, t(9 : 22) [4], 46,XY[16]- 46% | 0 | 341 | 8.3 | No progression | Dasatinib | Hospice after 7m following sepsis | [9] | 55 | F | RAEB I | 45XX,−4,t(9; 22)(q34; q11.2) | 6 | 10 | 10.3 | No progression | Supportive care | Died in 1 month sepsis | [10] | 31 | M | RAEB II | 44–45XY,der(4),−5,der(7),−7,−8,t(9; 22)(q34; q11.2),−15,+22 | 14 | 54 | 4.7 | No progression | Supportive | Died in 1 week - IC bleed? | [10] | 65 | M | RAEB 2 | 44xy del 5,-7,-14,-16 + mar | 18 | n/a | n/a | No progression | None | Died in 1 m from lung cancer | [11] | 67 | M | RAEB1-> RAEB 2 | 45,XY,+3,−5,−7,−20,+mar,+mar/45,XY, | 4 | 52 | 10.4 | No progression | Imatinib for 2 weeks f/b supportive care | Died 1 yr from fungal pneumonia | [12] | +3,−4,−8,−9,−11,−18,−20,−21,−21,+mar,+mar | | | | | | | | 61 | M | MDS unclassifiable | 46,XY,der(5; 12)(q10; q10)+mar[3]/46,XY[12] t(9; 22)by FISH in der(5; 12) | n/a | n/a | n/a | n/a | Imatinib, hydroxyurea, cytarabine | Died in 5m from resp failure | [13] | 71 | M | RAEB | 46XX,der(12)t(12; 17)(p11.2; q11.2)[7]/46, XX[9] | 10 | 54 | 9 | To RAEBt in 5 m | Hydroxyurea | Died in 4 m from pneumonia | [14] | 66 | F | RAEB | 47,XX,+8, t(9; 22; 16)(q34; q11.2,q23)[4] | 2 | 275 | 7.5 | Progressed to granulocytic sarcoma of skin in 9 m | Supportive care | Died 1 m later | [14] | 59 | M | RAEB | 46,XY,t(9; 22)(q34; q11) | 4 | 78 | 9.2 | 4 m to AML | Imatinib | Alive after HCT | [14] | 67 | F | RAEB 2 | 46,XX[1]/46,XX,t(9; 22)(q34; q11)[29] | 10 | 114 | 11.5 | NA | Conventional chemotherapy with rising blast % responded to imatinib. | Alive at 14 m after imatinib | [15] | 73 | M | RAEB | 46 XT t(9 : 22), | 8 | n/a | n/a | CML in 2.5 yr f/b blast crisis in 3 m | Imatinib | Died with refractory CML and pneumonia | [16] | 78 | M | RAEB t | 46,XY der (3), t(1 : 3)(p22:p14), t(9; 22) | 22.2 | 29 | 9.8 | n/a | Ara-C+daunorubicin->AraC+IDarubicin | Died from pneumonia 5 m after Dx | [17] | 69 | M | RAEBt | +Y, del5,q13q34,+8,+13,+14, p11+22, t922q34 | 14 | 46 | 8.1 | 2 m to AML | Vindesine f/b cytosine arabinoside, mitoxantrone, tenoposide | Died from pneumonia 5 m after Dx | [18] | 64 | M | RAEB | +8, t(9 : 22)(q34)- 46% | 4 | 98 | 7.8 | 9 M to AML | Hydroxyurea f/b cyt ara-c, teniposide | Died from sepsis 9 m after Dx | [18] | 30 | M | MDS | 46,XY[1]/46,XY,t(9; 22)(q34; q11)[45] | 0.5 | 30 | 12.5 | No progression | n/a | Died 2 years after due to intracranial bleeding | [19] | 78 | F | RAEB 2 | 46 XX, t(9; 22)(q 34; q 11) | 11.7 | 21 | 8 | 5 m to AML | Transfusion, ubenimex | Died from pneumonia | [20] | 73 | M | MDS | 46,XY[54]/46,XY,t(4; 6)(p15; p12),t(9; 22) (q34; q11)[6] | 1 | 120 | 15.4 | 7 m to CMML | Supportive care | Died from bleeding 10 m after dx | [21] | 85 | M | RAEB | 46,XY,t(9; 22)(q34; q11) | 25 | 120 | 9.8 | 17 m to AML | Daunorubicine, cytarabine, 6-mercaptopurine. Prednisone f/b 6-mercaptopurine, hydroxyurea. | Died 21 m later | [22] | 62 | M | MDS | 46,XY[?]/t(?; 11; 22)(?; q11; q11),t(9; 22)(q34; q11), −5,−7,+8,−12 | 8.2 | 3 | 11.9 | 3 m to RAEBt | Prednisolone and vit D3 | Died 3 m later from pneumonia, bleeding | [23] | 70 | FM | RARS | 46,XX[3]/46,XX,t(9q; 22q)[12] | n/a | 316 | 9.5 | No progression | Pyridoxine, nandrelone, folinic acid | Alive at 45 months | [24] | 49 | F | MDS | 46 XX (3) t(9 : 22) 34 : 11 | n/a | 425 | 8.2 | 32M TO AML | Ara-C, 6-thioguainine, daunomycin | Died from pneumonia 1 m after AML | [25] | 78 | F | MDS-RARS | 46,XX--> 46,XX,t(9; 22)(q34; q11) | 14 | 152 | 10.2 | 26 m to CML blast crisis | Imatinib and nilotinib | Hematologic response on TKI | [26] | 83 | M | MDS-RCMD | 46 XY--> 46,XY,t(9; 22)(q34; q11.2)[10]/46,XY[5] | <1 | 90 | 11.6 | No progression | Imatinib-->dasatinib->nilotinib | Alive after 30 months | Case |
|
|